1984 Volume 58 Issue 12 Pages 1289-1304
The efficacy and safety of non-steroidal analgesic/anti-inflammatory agent, Flurbiprofen were compared those of Ibuprofen in patients with acute upper respiratory tract inflammation by a double blind method. The result were as follows:
1. Final glocal improvement rate in the Flurbiprofen group (120 mg/day) was 59.2% and 59.3% in the Ibuprofen group (600 mg/day), showing no significant difference between two groups. However, the cases of excellent improvement were more in Flurbiprofen group (18.4%) than Ibuprofen group (14.8%).
2. The development of the effect was early after administration of the drug in flurbiprofen group than Ibuprofen group, especially in the symptoms of muscle pain, joint pain and hoaseness (p<0.05).
3. The incidence of side effects in Flurbiprofen was 5.1% and 2.4% in the Ibuprofen group, and there was no signicant difference between two groups.
4. In global utility rate, usefulness was 60.0% in the Flurbiprofen group and 61.2% in the Ibuprofen group, showing no significant difference between two groups. However, the case of excellent usefulness were more in Flurbiprofen group than Ibuprofen group.
From these result, it is concluded that Flurbiprofen is a useful drug for the treatment on acute upper respiratory tract inflammation and that the clinical efficacy and safety of Flurbiprofen were slightly better than Ibuprofen.